Hormone Optimization for Women’s and Men’s Health Benefits

Integrative Hormone Health, Receptors, and Real-World Care: How I Combine Bioidentical Therapy, Functional Strategies, and Chiropractic To Restore Energy, Mood, Pain, Bone, and Brain

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the latest, evidence-based understanding of hormone health and how I translate research into safe, individualized care. I explain why the molecule, dose, and delivery route matter; how bioidentical 17β-estradiol and micronized progesterone differ from synthetic counterparts; and what that means for the heart, brain, breast, bones, and metabolism. I detail the receptor biology that underpins outcomes, including ERα/ERβ, PR-A/PR-B, AR, and thyroid receptors, and I elaborate on venous thromboembolism differences between oral and transdermal estrogen, the Women’s Health Initiative context, and the prostate saturation model for men on testosterone therapy. I also show how integrative chiropractic care, targeted nutrition, sleep optimization, autonomic balance, and progressive strength training amplify hormonal benefits in real life. Throughout, I reference leading researchers who use modern, evidence-based methods and include hyperlinks to peer-reviewed sources, as well as clinical observations from my practice.

Why Hormones Matter In Real Life: My Patient-Centered Lens

When patients arrive in my clinic exhausted, in pain, and discouraged, they often feel they have tried everything. What I do first is align biology with their goals. The core truths I use to orient our work are simple but powerful:

• The molecule matters.
• The route of administration matters.
• The context of your physiology and risks matters.

This clarity lets me match therapy to receptor biology and to your lived experience. If a study shows harm with a certain hormone, I immediately ask: Which molecule? Which dose? What route? What was the patient population and timing? Those variables frequently explain the outcomes. In practice, the right molecule, at the right dose, via the right route, at the right time, makes all the difference.

The Evidence Reframed: What The Women’s Health Initiative Did And Did Not Show

Early 2000s headlines said, “Hormones are harmful.” The Women’s Health Initiative (WHI) primarily tested oral conjugated equine estrogens (CEE), with or without medroxyprogesterone acetate (MPA), in older women many years past menopause. That methodological framing is relevant for biology and outcomes:

• Oral estrogens undergo first-pass hepatic metabolism, which increases clotting factors and inflammatory mediators, thereby shifting cardiovascular risk.
• CEE is not human 17β-estradiol; MPA is not micronized progesterone. Each has distinct receptors and metabolic effects.

When I select therapy, I prioritize transdermal 17β-estradiol and oral micronized progesterone because transdermal routes minimize hepatic prothrombotic shifts and micronized progesterone behaves differently from synthetic progestins with respect to vascular, brain, and breast endpoints (Canonico et al., 2007; Scarabin, 2018; Stuenkel et al., 2015). Notably, extended WHI follow-up showed that in women without a uterus, estrogen-alone (CEE) was associated with lower breast cancer incidence and mortality versus placebo, underscoring that “all hormones are harmful” was an overgeneralization (Chlebowski et al., 2020; Manson et al., 2013). The clinical lesson is nuance: molecule, route, timing, and patient selection govern risk.

Oral Versus Transdermal Estrogen: Why Route Changes Physiology And Risk

The route of estrogen delivery reshapes physiology:

• With oral estrogen:
  • First-pass through the liver increases synthesis of fibrinogen and clotting factors VII and X and can raise triglycerides and C-reactive protein.
  • This hepatic activation elevates the risk of venous thromboembolism and can offset vascular benefits.
• With transdermal 17β-estradiol:
  • The liver’s first-pass is bypassed.
  • Coagulation factor induction is minimized, lowering thrombotic risk compared with oral forms (Canonico et al., 2007; Scarabin, 2018).

In my clinic, I favor transdermal estradiol, particularly for patients with migraines with aura, metabolic syndrome, dyslipidemia, or elevated venous thromboembolism risk. If the uterus is intact, I pair estradiol with micronized progesterone to protect the endometrium. Patients typically experience steadier symptom relief, fewer side effects, and improved tolerability with this physiology-first approach.

Bioidentical Versus Synthetic: The Receptor-Level Reasoning

Words matter, and so does molecular structure. Bioidentical hormones match the body’s natural ligands, activating receptors in a manner closer to physiology:

• Micronized progesterone binds PR-A and PR-B with natural affinity and has neurosteroid properties through GABA-A modulation that can support sleep and reduce anxiety.
• Several synthetic progestins have off-target glucocorticoid or androgenic effects that can alter vascular tone, lipid levels, and breast tissue signaling in ways different from progesterone (Fournier et al., 2008; Stuenkel et al., 2015).

Clinically, this difference translates into better sleep, a more stable mood, and a breast cancer risk profile that appears more favorable with progesterone compared with some progestins in observational data (Fournier et al., 2008). When reviewing research, I always verify the exact compound, dose, and route, because “progestogen” is not the same as “progesterone,” and outcomes diverge at the receptor and tissue levels.

Menstrual Cycle And Lifespan Physiology: A Map For Treatment Choices

To understand perimenopause and menopause, we revisit normal physiology:

• Estrogen supports endothelial function, bone, synaptic plasticity, and metabolic regulation.
• Progesterone organizes endometrial stability, tempers proliferation, and exerts calming neurosteroid effects.
• Testosterone influences libido, mitochondrial biogenesis, muscle integrity, and mood in all individuals.

In the follicular phase, estradiol rises and promotes endometrial proliferation; after ovulation, progesterone peaks, stabilizing the tissue and mood. Menopause collapses this choreography. The result is vasomotor symptoms, joint and tendon pain, sleep fragmentation, cognitive fog, and mood variability. Reinstating physiologic signaling with the right molecules, timing, and delivery helps restore balance.

Estrogen, Progesterone, Testosterone, And Thyroid: Integrating The Receptor Network

The body is a network, not a set of single switches:

• ERα/ERβ are widely distributed across the brain, bone, vasculature, and immune cells. Estradiol’s balanced activation of these receptors underlies benefits in endothelial nitric oxide signaling, glucose transport in the brain, and osteoclast restraint (Brinton, 2009).
• PR-A/PR-B orchestrate endometrial gene networks and influence neuroinflammation and myelination; progesterone’s metabolites, including allopregnanolone, enhance inhibitory GABAergic tone for sleep and anxiety relief (Schüle et al., 2011).
• The androgen receptor (AR) governs muscle, bone, vascular, and dopaminergic tone, and testosterone’s conversions to estradiol (via aromatase) and DHT (via 5α-reductase) are essential for tissue-specific function (Finkelstein et al., 2013).
• Thyroid receptors are nearly ubiquitous, regulating basal metabolic rate, mitochondrial function, and neural tempo; subclinical hypothyroidism can amplify perimenopausal symptoms and blunt cardiometabolic progress unless addressed (Biondi & Cooper, 2008).

In care plans, I assess and correct deficits across this receptor network because restoring a single ligand without the broader context often limits results.

Testosterone Optimization In Men: Prostate Saturation, Brain Health, And Cardiometabolic Safety

A persistent myth says testosterone “fuels” prostate cancer. Modern data and the prostate saturation model tell a different story: prostatic androgen receptors reach functional saturation at relatively low serum testosterone; beyond that threshold, further increases do not proportionally stimulate the gland (Loeb et al., 2017). Large cohorts do not show higher prostate cancer incidence with higher endogenous testosterone (Herschman et al., 2017). For selected men after prostate cancer therapy and with stable PSA and no evidence of disease, carefully monitored testosterone therapy can be considered, often improving quality of life without increasing recurrence in contemporary series (Kaplan et al., 2015).

From a brain and longevity perspective, low testosterone is associated with a higher risk of cognitive decline; men in the lowest quintile face significantly greater dementia risk than those in higher quintiles (Yeap et al., 2018). Mechanisms include diminished hippocampal synaptic plasticity, impaired endothelial function, and disrupted sleep architecture. In cardiometabolic domains, meta-analyses show no increase in major adverse cardiovascular events when testosterone is used to correct documented hypogonadism with physiologic dosing and monitoring (Hudson et al., 2022; Corona et al., 2022). In my clinic, titrating to the upper-quartile youthful range—without supraphysiology—and combining therapy with resistance training, sleep optimization, and nutrition consistently improves body composition, energy, and mood.

Women And Androgens: Precision Beyond Flawed Ranges

Women need androgens for libido, energy, lean mass, and cognitive clarity. Some lab reference ranges even include “zero,” which conflicts with receptor biology. I rely on symptoms, free androgen indices, and function:

• When I consider low-dose testosterone in women: hypoactive sexual desire, persistent fatigue, impaired exercise recovery, and cognitive fog after excluding other causes (Davis et al., 2019).
• Monitoring: I use the lowest effective dose, watch for virilizing effects, track lipids and liver markers, and titrate based on function and safety.

Often, combining transdermal estradiol with micronized progesterone and a carefully dosed androgen layer produces broader relief, especially for sleep, mood, and musculoskeletal discomfort.

Breast Cancer, Estrogen, Progesterone, And Androgens: The Receptor Context

Cancer risk and survivorship require receptor literacy:

• ERα activation can upregulate survival proteins such as BCL-2, while ERβ may counterbalance proliferation in some contexts. PR isoforms (PR-A, PR-B) modulate ER signaling and differentiation (Duarte et al., 2019; Graham & Clarke, 1997).
• The androgen receptor in breast tissue can oppose ER-driven proliferation in certain phenotypes; this crosstalk is clinically relevant for symptom control and potentially for disease biology in selected patients (Gucalp et al., 2013).

Tamoxifen antagonizes ERα to reduce recurrence in ER+ disease; aromatase inhibitors (AIs) lower estrogen production but often cause musculoskeletal pain and fatigue. In select contexts and under oncologic supervision, carefully dosed physiologic androgen support can improve AI tolerability and adherence and may exert antiproliferative effects depending on tumor AR/ER/PR status (Glaser & Dimitrakakis, 2013; Glaser et al., 2019). The overarching rule is individualized care with oncology collaboration; we aim for physiologic restoration, not supraphysiologic exposure, and we monitor meticulously.

Bone Health And Mechanotransduction: Hormones, Strength, And Microarchitecture

Osteoporosis is a failure of coupled remodeling. Sex hormones, loading, and nutrients shape bone quantity and quality:

• Estradiol restrains osteoclasts and supports osteoblast survival; testosterone increases periosteal apposition and lean mass and reduces marrow adiposity (Khosla & Monroe, 2018).
• Bone adapts to mechanical strain via osteocyte signals (Wnt/β-catenin, sclerostin modulation), which is why progressive resistance and power training are essential (Bonewald, 2011).
• In hypogonadal men and postmenopausal women, restoring physiologic sex steroid signaling improves bone turnover markers, supports BMD, and increases the osteogenic response to training. In high-risk women, anabolic agents followed by antiresorptives can amplify gains (Cosman et al., 2017; The North American Menopause Society, 2022).

In my programs, I set protein at roughly 1.2–1.6 g/kg/day, bring 25(OH)D into 30–50 ng/mL unless otherwise indicated, and build a progressive strength and balance plan. Integrative chiropractic care reduces pain barriers and corrects mechanics to make training effective and safe.

Integrative Chiropractic Care: Aligning Autonomics, Mechanics, And Recovery With Endocrine Care

Hormones do not operate in isolation; they are embedded in a nervous system that governs sleep, pain, and recovery. My integrative chiropractic care focuses on neuromechanics and autonomic balance to enhance endocrine outcomes:

• Autonomic rebalancing: Gentle spinal and rib mobilization, diaphragmatic breathing, and vagal-tone practices reduce sympathetic overdrive that disrupts GnRH/LH/FSH and cortisol rhythms. Patients sleep better, and progesterone’s GABAergic benefits become more evident (Budgell & Hirano, 2001).
• Pain modulation: By lowering nociceptive input and central sensitization, we reduce the inflammatory burden that blunts sex steroid and thyroid signaling. This accelerates improvements in mood, movement, and glycemic control.
• Mechanotransduction: Correcting posture, gait, and joint centration allows progressive resistance training to safely generate the strain-rate signals bones require. With optimized hormones, tissues remodel more robustly.
• Lymphatic and fascial dynamics: Restoring rib cage motion and diaphragmatic function improves lymphatic return and cardiorespiratory coupling, which synergizes with omega-3/anti-inflammatory nutrition and vitamin D for systemic recovery.

Clinically, when I layer chiropractic care onto hormone therapy, patients report earlier improvements in sleep, fewer headaches, more comfortable movement, and greater adherence to training. You can see case narratives and practical examples at WellnessDoctorRx and on my professional updates.

• WellnessDoctorRx: https://wellnessdoctorrx.com/
• LinkedIn: https://www.linkedin.com/in/dralexjimenez/

Functional And Lifestyle Medicine: Preparing The System So Hormones Work

Bioidentical therapy unlocks physiology only if the system is prepared. I build foundations that magnify hormonal benefits:

• Nutrition:
  • Focus on eating more protein, omega-3s, magnesium, and polyphenols to help blood vessel health, energy production, and estrogen processing through
  • In insulin resistance, pair structured protein distribution with resistance training and post-meal walking to improve glucose disposal.
• Sleep:
  • Consolidate sleep to align with testosterone’s nocturnal rhythms and progesterone’s GABAergic actions. Screen and treat sleep apnea; it undermines endocrine and cognitive gains.
• Stress and autonomics:
  • Use breath training, sunlight exposure, time in nature, and chiropractic care to recondition autonomic tone. Lower sympathetic load restores hypothalamic sensitivity and circadian coherence.
• Environmental exposures:
  • Limit endocrine disruptors (certain plastics, pesticides) that interfere with receptor signaling and hepatic metabolism.

These layers are not extras; they are prerequisites for durable outcomes.

Practical Protocols: How I Sequence And Monitor Care

I practice lab-sparing but safety-focused medicine. Most decisions are clinically obvious with a careful history, exam, and clear goals; labs confirm safety and refine precision.

• Baseline mapping:
  • Symptoms: sleep, vasomotor issues, libido, mood, energy, pain, cognition.
  • Labs: estradiol (sensitive assay when needed), progesterone (per context), total and free testosterone with SHBG, LH/FSH, thyroid panel, CBC/CMP, fasting insulin/glucose, HbA1c, lipids (with ApoB when available), hs-CRP, vitamin D, ferritin; PSA and DRE for men as appropriate.
  • Imaging: DXA for bone and body composition, where indicated.
• Hormone therapy:
  • Women: Prefer transdermal 17β-estradiol; pair with oral micronized progesterone if uterus present. In select cases, consider carefully titrated low-dose testosterone with monitoring.
  • Men: Correct hypogonadism with transdermal, injectable, or implant modalities tailored to kinetics and adherence. I target a youthful-physiology window and monitor estradiol, hematocrit, PSA, and lipids.
• Monitoring cadence:
  • Recheck labs 6–12 weeks after changes; then every 3–6 months.
  • Track functional endpoints: sleep quality, HRV, pain and mood scales, sexual function, body composition, and strength tests.
• Bone and movement integration:
  • Progressive resistance training 2–4 days/week; power elements when safe to activate osteogenesis.
  • Chiropractic care for joint play, postural respiration, and pain reduction to enable consistent loading stimuli.
• Cardiometabolic integration:
  • Zone 2 aerobic training for mitochondrial conditioning, fiber-rich meals, and circadian meal timing.
  • Omega-3 index and vitamin D optimization for endothelial, immune, and autonomic synergy.

This stepwise approach explains why each element is chosen and how it interfaces with receptor biology and tissue remodeling.

Clinical Observations From My Practice: What Patients Experience

In my integrative practice, when we synchronize hormones with mechanics and metabolism:

• Women on transdermal estradiol plus micronized progesterone report faster relief of hot flashes, deeper sleep within weeks, steadier mood, and improved sexual comfort. Adding carefully dosed androgen support often accelerates improvements in energy, focus, and joint comfort.
• Men optimized to a physiologic upper-quartile testosterone range frequently report restored morning vitality, better stress tolerance, clearer thinking, and improved training capacity. With resistance training and nutrition, DEXA often shows gains in lean mass and reductions in visceral fat; HbA1c and blood pressure improve.
• Patients on aromatase inhibitors who struggle with arthralgia often regain function when we combine lymphatic and rib mobility work, progressive strength, vitamin D and omega-3 optimization, sleep consolidation, and, in select oncology-coordinated cases, symptom-directed androgen strategies. Adherence to oncologic therapy improves as pain and fatigue decline.

These outcomes match the science: when receptor sites are refilled by the right ligands and the body is primed with sleep, nutrients, movement, and autonomic balance, systems remember how to function well.

Safety, Cardiovascular Risk, And Prostate Or Breast Considerations

Safety is a process, not a promise. My protocols include:

• Men on testosterone:
  • Monitor hematocrit and mitigate erythrocytosis with dose adjustments or phlebotomy as needed.
  • Track PSA kinetics, contextualize rises (infection, instrumentation, ejaculation), and collaborate with urology. Respect the prostate saturation concept while never ignoring clinical red flags (Loeb et al., 2017).
  • Cardiometabolic vigilance with blood pressure, lipids, and insulin sensitivity; meta-analytic data are reassuring when therapy is physiologic and monitored (Hudson et al., 2022; Corona et al., 2022).
• Women on estrogen/progesterone:
  • Use bioidentical estradiol and micronized progesterone; transdermal routes mitigate thrombotic risk (Canonico et al., 2007; Scarabin, 2018).
  • Provide endometrial protection when the uterus is present; avoid relying on topical-only progesterone for uterine safety.
  • Follow breast and gynecologic screening guidelines; coordinate closely with oncology for any oncology history.
• Bone and vascular:
  • Sequence osteoporosis therapy thoughtfully; use anabolic-first strategies in very high-risk patients, followed by antiresorptives to preserve gains (Cosman et al., 2017).
  • Consider omega-3 index and vitamin D targets for vascular and immune coherence, rechecking as dosing changes (Harris et al., 2021; Manson et al., 2019).

Precision, monitoring, and shared decision-making maintain safety while unlocking benefits.

Actionable Next Steps: Building Your Plan

• Ask for a comprehensive assessment: symptoms, movement, sleep, cardiometabolic risk, and targeted labs for change management.
• If you are a candidate, consider transdermal estradiol and oral micronized progesterone (uterus present), with thoughtfully dosed testosterone when indicated and monitored.
• Integrate chiropractic care for autonomic balance, pain modulation, and movement mechanics that make training effective.
• Commit to resistance training 2–4 days each week, plus zone 2 conditioning for mitochondria and glycemic control.
• Optimize omega-3 index and vitamin D, and structure protein at 1.2–1.6 g/kg/day unless contraindicated.
• Reassess regularly with symptom scales, labs, and functional tests; adjust iteratively based on outcomes.

This whole-person, evidence-based roadmap respects receptor biology and honors how real people change.

References

• Arevalo, M.-A., Azcoitia, I., & Garcia-Segura, L. M. (2015). The neuroprotective actions of oestradiol and oestrogen receptors. Nature Reviews Neuroscience, 16(1), 17–29.
• Biondi, B., & Cooper, D. S. (2008). The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews, 29(1), 76–131.
• Bonewald, L. F. (2011). The amazing osteocyte. Journal of Bone and Mineral Research, 26(2), 229–238.
• Brinton, R. D. (2009). Estrogen-induced plasticity from cells to circuits: Predictions for cognitive function. Trends in Pharmacological Sciences, 30(4), 212–222.
• Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens. Circulation.
• Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Estrogen-alone therapy and invasive breast cancer incidence and mortality: Extended follow-up of the Women’s Health Initiative randomized clinical trial. JAMA Oncology.
• Cosman, F., Crittenden, D. B., Adachi, J. D., et al. (2017). Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine, 377(15), 1417–1427.
• Corona, G., Goulis, D. G., Huhtaniemi, I. T., et al. (2022). The effect of testosterone replacement therapy on cardiovascular risk in men: An updated systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 107(6), e2291–e2311.
• Davis, S. R., Baber, R., Panay, N., et al. (2019). Global consensus position statement on the use of testosterone therapy for women. The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666.
• Finkelstein, J. S., Lee, H., Burnett-Bowie, S.-A. M., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. The New England Journal of Medicine, 369(11), 1011–1022.
• Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment.
• Glaser, R. L., & Dimitrakakis, C. (2013). Reduced breast cancer incidence in women treated with subcutaneous testosterone, with or without anastrozole. Maturitas, 76(4), 342–349.
• Glaser, R. L., York, A. E., & Dimitrakakis, C. (2019). Subcutaneous testosterone letrozole implants in breast cancer survivors with aromatase inhibitor intolerance. Maturitas, 128, 1–6.
• Graham, J. D., & Clarke, C. L. (1997). Physiological action of progesterone in target tissues. Endocrine Reviews, 18(4), 502–519.
• Gucalp, A., Tolaney, S., Isakoff, S. J., et al. (2013). Phase II study of bicalutamide in patients with androgen receptor–positive, estrogen receptor–negative metastatic breast cancer. Clinical Cancer Research, 19(19), 5505–5512.
• Harris, W. S., Tintle, N. L., Imamura, F., et al. (2021). Omega-3 fatty acids and cardiovascular disease: New insights from population, genetics, and intervention studies. Atherosclerosis, 330, 1–10.
• Herschman, J. D., Tosoian, J. J., Fleet, J. C., et al. (2017). Endogenous testosterone and prostate cancer risk: Population studies and mechanistic insights. JAMA.
• Hudson, J., Jones, T. H., & Channer, K. S. (2022). Testosterone therapy and cardiovascular risk: A critical review of the literature. European Cardiology Review, 17, e21.
• Kaplan, A. L., Hu, J. C., Morgentaler, A., et al. (2015). Testosterone therapy in men with prostate cancer. Journal of Urology.
• Khosla, S., & Monroe, D. G. (2018). Regulation of bone metabolism by sex steroids. Cold Spring Harbor Perspectives in Medicine, 8(1), a031211.
• Loeb, S., Folkvaljon, Y., Damber, J.-E., et al. (2017). Testosterone, PSA, and prostate cancer risk: Saturation and clinical interpretation. European Urology, 72(3), 448–455.
• Maki, P. M., & Kornstein, S. G. (2017). Menopause and cognitive decline: Current perspectives of the critical window hypothesis. Menopause.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during and after the Women’s Health Initiative trials. JAMA.
• Manson, J. E., Cook, N. R., Lee, I.-M., et al. (2019). Vitamin D supplements and prevention of cardiovascular disease and cancer: The VITAL randomized clinical trial. New England Journal of Medicine, 380(1), 33–44.
• Scarabin, P.-Y. (2018). Progestogens and venous thromboembolism in menopausal women: An updated oral versus transdermal estrogen meta-analysis. Climacteric.
• Schüle, C., Eser, D., & Baghai, T. C. (2011). Neuroactive steroids in depression: Evidence for a role of allopregnanolone. CNS Spectrums, 16(2), 103–110.
• Stuenkel, C. A., Davis, S. R., Gompel, A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011.
• The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 1–39.
• WellnessDoctorRx by Dr. Alexander Jimenez. Clinical insights and integrative protocols.
• Dr. Alexander Jimenez on LinkedIn.
• Yeap, B. B., Alfonso, H., Chubb, S. A. P., et al. (2018). Endocrine factors and risk of cognitive decline: Longitudinal studies in men. Journal of Clinical Endocrinology & Metabolism.